Texas Clinical Trials for Pleural Mesothelioma
1. Baylor College of Medicine Houston
Name of Study:
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Study type:
Interventional
Purpose:
To determine whether MEDI4736 or combination MEDI4736 and tremelimumab are associated with changes to the immunologic environment in subjects undergoing resectional surgery
ClinicalTrials.gov Identifier:
NCT02592551
Status:
Currently Recruiting, 20 patients, May 2016 – June 2018
Location:
Baylor St. Lukes Houston
Contact:
Michelle G. Almarez, BBA
713-798-3680
michelle.almarez@bcm.edu
Chapter 2
Bryan Burt, MD
713-798-8266
bryan.burt@bcm.edu
2. University of Texas MD Anderson Cancer Center, Houston, TX
Name of Study:
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Study type:
Interventional
Purpose:
The goal of this clinical research study is to learn if alisertib can help to control mesothelioma. The safety of this drug will also be studied. This is an investigational study. Alisertib is not FDA- approved or commercially available. It is currently being used for research purposes only
ClinicalTrials.gov:
NCT02293005
Status:
Currently recruiting- Start date May 2015- Completion date May 2021; Estimated enrollment 58
Location:
University of Texas MD Anderson Cancer Center Houston Texas
Contact:
Anne S. Tsao MD
713-792-6363
3. University of Texas MD Anderson Cancer Center, Houston, TX
Name of Study:
Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma
Study type:
Interventional
Purpose:
The goal of this clinical research study is to assess the safety of pembrolizumab (also called MK-3475) after radiation therapy (with or without surgery and/or chemotherapy) in patients with malignant pleural mesothelioma.
ClinicalTrials.gov:
NCT02959463
Status:
Not yet open for participant recruitment. Start Date: March 2017, Completion Date: March 2020 Estimated Enrollment: 24
Location:
University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030
Contact:
Daniel Gomez, MD
713-563-2300
4. University of Texas MD Anderson Cancer Center, Houston, TX
Name of Study:
Trial of Adcetris in CD30+ Malignant Mesothelioma
Study type:
Interventional
Purpose:
The goal of this clinical research study is to learn if Adcetris (brentuximab vedotin) can help to control mesothelioma. The safety of this drug will also be studied.
ClinicalTrials.gov:
NCT03007030
Status:
Not Yet Recruiting- March 2017, Completion date March 2022; Estimated enrollment 50
Location:
University of Texas MD Anderson Cancer Center Houston Texas
Contact:
Anne S. Tsao, MD
713-792-6363
Mesothelioma Clinical Trial Information
Learn More About Mesothelioma
Did You Know?
Get Help from Experienced Mesothelioma Nurses
Learn more about these experienced mesothelioma nurses by watching the video below. Click here to contact a mesothelioma nurse now.
Learn More About MesoLawyersCare
Watch the video below to learn why MesoLawyersCare is the best choice to represent you and your family after a mesothelioma diagnosis.
Contact MesoLawyersCare Now
If you or a loved one has been diagnosed with mesothelioma, please contact us to see if we can help you get the compensation you deserve from the billions of dollars in asbestos trust funds available now for qualified asbestos victims. With just one call, you can put all our experience and success to work for you.
We have represented thousands of victims of mesothelioma and their families in virtually every State in the country and in decades of work have recovered billions of dollars in financial compensation for our clients.
Call us now at 1-888-568-1177, fill out the form on this page or chat with a live person. The consultation is free and it costs nothing upfront to hire the lawyers behind MesoLawyersCare. We only get paid if you collect a settlement or verdict and you will never receive a bill from us.
Receive a
FREE No Obligation
Legal Consultation Today
Important Notice: We are unable to help if:
- Diagnosis or passing was more than three years ago
- An attorney has already been retained in this matter
“You have all been so wonderful to us, so professional, and always looking out for our best interests in every way. I know it’s a job you do. However, not once did anyone ever make us feel like we did not matter.”